Astellas Pharma Inc
OTC:ALPMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Astellas Pharma Inc
OTC:ALPMY
|
JP |
|
E
|
E Automotive Inc
OTC:EICCF
|
CA |
|
LNA Sante SA
PAR:LNA
|
FR |
|
I
|
Ionis Pharmaceuticals Inc
XMUN:ISI
|
US |
|
RCL Foods Ltd
OTC:RCLFF
|
ZA |
|
E
|
Epsilon Healthcare Ltd
ASX:EPN
|
AU |
|
K
|
Ktbst Mixed Freehold and Leasehold Real Estate Investment Trust
SET:KTBSTMR
|
TH |
Intrinsic Value
Is ALPMY undervalued or overvalued?
See the intrinsic value estimate for 
Astellas Pharma Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Astellas Pharma Does
Astellas Pharma is a Japanese drug company that discovers, develops, makes, and sells prescription medicines. Its main products treat areas such as urology, transplant medicine, immunology, cancer, and eye disease. The company spends heavily on research and then brings branded drugs through testing, approval, manufacturing, and distribution.
- Headquarters
- Japan JP
- Employees
- 13 643
- IPO date
- May 16, 1949
Astellas Pharma has no economic moat
Patent protection keeps copies of individual Astellas medicines out temporarily, but does not provide lasting protection across the business. Generic competition has reduced Myrbetriq sales, while competing treatments give doctors alternatives to medicines such as Xtandi.
Read the full moat analysis
Revenue & Expenses Breakdown
Astellas Pharma Inc
Earnings Waterfall
Astellas Pharma Inc
The intrinsic value for Astellas Pharma Inc (ALPMY) under the Base Case is hidden USD.
Compared with the current market price of 16.21 USD, the stock appears hidden.
